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1.0  INTRODUCTION 
The pharmaceutical analysis is a branch of chemistry, which involves the series of 
process for the identification, determination, quantitation, and purification. This is mainly 
used for the separation of the components from the mixture and for the determination of the 
structure of the compounds. The different pharmaceutical agents are Plants, Minerals 
Microorganisms and Synthetic compounds1 
 Pharmaceutical analysis plays a vital role in the Quality Assurance and Quality 
control of bulk drugs. Analytical chemistry involves separation, identification, and 
determining the relative amounts of components in a sample matrix; Pharmaceutical 
analysis is a specialized branch of analytical chemistry that derives its principles from 
various branches of sciences like physics, microbiology, nuclear science, and electronics 
etc. Qualitative analysis is required before a quantitative analysis can be undertaken. 
  A separation step is usually a necessary part of both a qualitative and quantitative 
analysis. The result of typical quantitative analysis can be computed from two 
measurements. One is the mass or volume of sample to be analyzed and the second one is 
the measurement of some quantity that is proportional to the amount of analyte in that 
sample and normally completes the analysis. 
The main steps that are performed during a chemical analysis are the following:  
(1) sampling, 
(2) field sample pretreatment,  
(3) laboratory treatment,  
(4) laboratory assay,  
(5) calculations, and  
(6) Results presentation.  
 Each must be executed correctly in order for the analytical result to be accurate. 
Some analytical chemists distinguish between an analysis, which involves all the steps, and 
an assay, which is the laboratory portion of the analysis2 
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The complete analysis of a substance consists of 5 main steps. 
 1. Sample preparation / Sampling 
2. Dissolution of the sample,  
3. Conversion of the analyte into a form suitable for measurement. 
4. Measurement 
5. Calculation and interpretation of the measurement 
Need for pharmaceutical Analysis 
1. New Drug Development. 
2. Method Validation as for ICH Guidelines 
3. Research in Pharmaceutical Sciences 
4. Clinical Pharmacokinetic Studies 
 When promising results are obtained from explorative validation performed during 
the method development phase, then only full validation should be started. The process of 
validating a method cannot be separated from the actual development of method condition3 
1.1 Chromatographic Techniques 
 In 1903 a Russian botanist Mikhail Tswett produced a colorful separation of plant 
pigments through calcium carbonate column. Chromatography word came from Greek 
language chroma = color and graphein = to write i.e. color writing or chromatography 4, 5 
During 1970's, most chemical separations were carried out using a variety of techniques 
including open-column chromatography, paper chromatography, and thin-layer 
chromatography. However, these chromatographic techniques were inadequate for 
quantification of compounds and resolution between similar compounds. During this time, 
pressure liquid chromatography began to be used to decrease flow through time, thus reducing 
purification times of compounds being isolated by column chromatography. However, flow 
rates were inconsistent, and the question of whether it was better to have constant flow rate or 
constant pressure was debated6. High pressure liquid chromatography was developed in the 
mid-1970's and quickly improved with the development of column packing materials and the 
additional convenience of online detectors. In the late 1970's, new methods including reverse 
phase liquid chromatography allowed for improved separation between very similar 
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compounds.  By the 1980's HPLC was commonly used for the separation of chemical 
compounds. New techniques improved separation, identification, purification and 
quantification far above the previous techniques. Computers and automation added to the 
convenience of HPLC. Improvements in type of columns and thus reproducibility were made 
as such terms as micro-column, affinity columns, and Fast HPLC began to immerge.  By the 
2000 very fast development was undertaken in the area of column material with small particle 
size technology and other specialized columns. The dimensions of the General Introduction 
typical HPLC column are 100-300 mm in length with an internal diameter between 3-5 mm. 
The usual diameter of micro-columns, or capillary columns, ranges from 3 μm to 200 μm 7. In 
this decade sub 2 micron particle size technology (column material packed with silica 
particles of < 2μm size) with modified or improved HPLC instrumentation becomes a popular 
with different instrument brand name like UPLC (Ultra Performance Liquid Chromatography) 
of Waters and RRLC (Rapid Resolution Liquid Chromatography) of Agilent.   
Classification of Chromatographic Techniques  
I] According to the nature of stationary and mobile phase  
• Gas Solid Chromatography  
• Gas Liquid Chromatography  
• Solid Liquid Chromatography  
• Liquid Liquid Chromatography  
II] According to mechanisms of separation, chromatographic methods are divided into 
1. Adsorption chromatography  
2. Partition chromatography 
3. Ion exchange chromatography  
4. Ion pair chromatography  
5. Size exclusion or gel permeation chromatography  
6. Affinity chromatography  
7. Chiral phase chromatography 
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1.2INTRODUCTION TO HPLC 
High performance liquid chromatography is basically a highly improved form of 
column chromatography. Instead of a solvent being allowed to drip through a column under 
gravity, it is forced through under high pressures of up to 400 atmospheres.  
HPLC allows the use of very small particle size for the column packing material 
which gives a much greater surface area for interactions between the stationary phase and 
the molecules flowing past it. This allows a much better separation of the components of 
the mixture. Its simplicity, high specify and wide range of sensitivity makes it ideal for 
analysis of many drugs in both dosage forms and in biological fluid. 
1.2.1 TYPES OF HPLC TECHNIQUES  
A. Based on modes of separation: There are two modes, normal phase mode and reverse 
phase mode. 
i) Normal phase mode: In this mode, the stationary bed is strongly polar in nature (e.g., 
silica gel), and the mobile phase is nonpolar (such as n-hexane or tetrahydrofuran). Polar 
samples are thus retained on the polar surface of the column packing longer than less polar 
materials. 
ii) Reveres phase mode: Reverse-phase chromatography is the inverse of Normal phase 
mode. The stationary bed is nonpolar (hydrophobic) in nature, while the mobile phase is a 
polar liquid, such as mixtures of water and methanol or acetonitrile. Here the more 
nonpolar the material is, the longer it will be retained. Non-polar compounds in the mixture 
will tend to form attractions with the hydrocarbon groups because of vanderwaals 
dispersion forces. Since most of the drugs and pharmaceuticals are polar in nature, they are 
not retained for a longer time and eluted faster which is advantageous. Different columns 
used are ODS (octadecylsilane), C18, C8, C4 etc. 
B. Based on elution technique 
Isocratic separation: In this technique the same mobile phase combination is used 
throughout the process of separation, the same polarity or elution strength is maintained 
through the process. 
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Gradient separation: In this technique, a mobile phase combination of low polarity or 
elution strengths is used followed by gradually increasing the polarity or elution strengths. 
C. Based on the scale of operation:- 
Analytical HPLC: In this technique only analysis of the samples are done. Recovery of the 
samples for reusing is normally not done, since the sample used very low. Ex.µgm 
quantities. 
Preparative HPLC: In this technique individual fraction of pure compounds can be 
collected using fraction collector. The collected samples are reused. Ex. Separation of few 
grams of mixtures by HPLC. 
D. Based on the type of analysis 
Qualitative analysis: It is done to identify the compound, detect the presence of impurity, 
to find out the number of components etc... This is done by using retention time values. 
 Quantitative analysis: It is done to determine the quantity of the individual or several 
components in a mixture.  This is done by comparing the peak area of the standard and 
sample.  
1.2.2 PRINCIPLE OF HPLC 
 The principle of separation in normal phase mode and reverse phase mode is 
adsorption and/or partition. 
ADSORPTION 
           When a mixture of components is introduced in to a HPLC column they travel 
according to their relative affinities towards the stationary phase. The component which has 
more affinity towards the stationary phase travels slower. The component which has less 
affinity towards the stationary phase travels faster. Since no two components have the same 
affinity towards the stationary phase the components are separated. 
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PARTITION 
  When a mixture of compounds are dissolved in the mobile phase and passed 
through a column of liquid stationery phase, the component which is more soluble in the 
stationery phase travels slower. The component which is more soluble in the mobile phase 
travels faster. Thus the components are separated because of the differences in their 
partition co-efficient. No two components have the same partition co-efficient for a 
particular combination of stationery phase, mobile phase and other conditions. 
1.2.3 INSTRUMENTATION OF HPLC 
The main components of HPLC system are as follows  
a) Mobile phase reservoir  
b) pumps  
c) Sample mixing units 
d) Sample injectors  
e) Column 
f) Detectors. 
g) Recorders and injectors 
 
 
Figure No 1:  Schematic diagram of HPLC 
a) Mobile phase Reservoirs: The modern HPLC apparatus is equipped with one or more 
glass or stainless steel reservoirs each of which contains 200-1000ml of a solvent. The 
mobile phase are often equipped with a mean of removing dissolved gasses usually oxygen 
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or nitrogen. These bubbles cause band spreading, in addition they often interfere with 
performance of the detectors. Often the systems also contain a means of filtering dust and 
particulate matter from the solvent to prevent these particles from damaging the pumping 
systems or clogging systems. This treatment removes gases as well as suspended matter. A 
separation that employs a single solvent of constant composition is termed as isocratic 
elution. Frequently separation efficiency is greatly enhanced by gradient elution. Here two 
difference solvent systems that differ significantly on polarity are employed.   
b) Pumps: The most important component of HPLC in solvent delivery systems is the 
pumps because its performance directly affects the retention time reproducibility and 
detector sensitivity. Three types of pumps each with its own set of advantages are 
encountered namely. 
 Reciprocating pumps 
 Displacement –type pumps  
 Pneumatic pumps 
Reciprocating Pumps 
 They usually consist of chamber in which the solvent is pumped by the back and 
forth motion of a motor drive piston. The two ball check valves which open and close 
alternately control the flow of solvent in to and (close alternately control the flow of 
solvent in to and) out of a cylinder track with the piston. 
ii) Displacement Pumps              
           Displacement pump consist of large, syringe like chambers equipped with a 
plunger that is activated by a screw driven mechanism powered by a stepping metor. The 
output is pulse free.  
iii) Pneumatic Pumps 
            The pneumatic pumps, the melphis contained in a compatible container housed 
in a vessel that can be pressurized by compressed gas. Pumps of this type are in expensive 
and pulse free, they suffer from limited capacity and pressure output as well as a 
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dependence of flow rate on solvent viscosity and column back-pressure. In addition they 
are not amiable to gradient elution and are limited to pressure less than about 2000psi.  
 c) Flow Control and Programming Systems 
 As part of their pumping systems, many commercial instruments are equipped 
with computer controlled devices for measuring the flow rate by determining the pressure 
drop across a restrictor located at the pump outlet. 
 d) Sample Mixing Units 
 Mixing unit is used to mix solvents in different proportions and pass through the 
column. They are Low pressure mixing chamber which uses helium for degassing solvents 
and High pressure mixing chamber does not require helium for degassing solvents. 
e) Sample Injector 
 Often the limited factor in the precision of liquid chromatographic measurement 
lies in the reproducibility with which samples can be introduced in to columns packing. 
Exaggerated by band broadening which accompanies overloading columns. These volumes 
used must be minuscule a (Thus, the volumes used must be mini) of a ml to perhaps 
500ml.It is convenient to be able to introduce the sample without depressurizing the 
system. 
f) Columns  
 HPLC columns are ordinarily constructed from smooth-bore stainless steel tubing, 
although heavy-walled glass tubing is occasionally encountered. 
Analytical columns 
 The majority of HPLC columns range in length from 10-30cm.Normally columns 
are straight with added length when needed, being gained by coupling two or more 
columns together occasionally called columns are encountered. 
 The inside diameter of liquid column is often 2-5mm.The most common particles 
size of packed columns is 5-10µm .the most common columns currently in use is one that is 
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15-25cm in length,4.6mm inside diameter ,and packed with 5µm particles. Columns of this 
type contain 4000-6000plates/meter. 
Guard columns 
 The guard columns have very small quantity of adsorbent and improve the life of 
the analytical columns. It also acts as a pre-filter to remove particulate matter and any other 
material. Guard column has the same material as that of analytical column but does not 
contribute to any separation. 
g) Column thermostats 
For many applications close control of column temperature is not necessary and 
columns are appareled at combined temperature often. However better chromatograms are 
obtained by monitoring column temperature constant to the few degree centigrade. Most 
modern commercial instruments are now equipped with column heaters that control, 
column temperature to a few tenths of degree from near obtained to 100-150 ºc. Columns 
may also be fitted with water jackets fed from a constant temperature bath to give precise 
temperature control. 
h) Column material 
The columns are made up of either stainless steel glass polyethylene, PEEK (poly ether 
ether ketone). Most widely used are stainless steel which can with stand high pressure. 
Latest ones are PEEK columns whose length varies from 5-30cm, diameter ranges from 2-
5mm and particle size from 1µ-20µ.Particle should be spherical and uniform in nature. 
Porous materials are used. Surface area of 1gm of stationary phase provides surface area 
ranging from 100-860 mts. 
i) Functional group 
 The functional group present in stationary phase depends on the type of 
chromatographic separation in normal phase mode it contain following groups  
o C18 –octadecylSilane (ODS) column 
o C8-octylcolumn   
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o C4-butyl column   
o CN-cyano column   
o NH2-amino column   
 
j) DETECTORS  
The function of detector in HPLC is to monitor the mobile phase as it emerges 
through the column 
Types of detectors  
Absorbance detector  
i) UV detector  
ii) Refractive index detector.   
iii) Flourimetric detector  
iv) Conductivity detector  
v) Amperometric detector  
vi) PDA detector  
 
k)  Recorders and integrators  
 
 Recorders are used to record the responses obtained from detectors after 
amplification, if necessary. They record the base line and all the peaks obtained, with 
respect time to time. Retention time for all the peaks can be found out from such 
recordings, but the area of individual peaks cannot be known.Integrators are improved 
variation of recorders with some data processing capabilities. They can be recorded the 
individual peaks with retention time, height and width of peaks, peak area, percentage of 
area, etc… integrators provide more information on peaks than recorders. Now a days the 
computers and printers are used for recording and processing the obtained data and for 
controlling several operations. 
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1.3 RP-UPLC 
UPLC is a chromatographic technique that can separate a mixture of compounds, 
and is used in biochemistry and analytical chemistry to identify, quantify and purify the 
individual components of the mixture. Utilizing a small packaging particle sizes columns 
and ultra-high pack pressure UPLC can be regarded as a new invention for liquid 
chromatography. The major differences between HPLC and UPLC are the use of smaller 
particles in the column of the UPLC and the greater pressure at which the UPLC operates. 
Advantages of this UHPLC is decreases the length of column, reduces solvent 
consumption& saves time. Therefore by using smaller particles, speed and peak capacity 
(number of peaks resolved per unit time in gradient separations) can be extended to new 
limits. The technology takes full advantage of chromatographic principles to run 
separations Using columns packed with smaller particles (less than2.5µm) and/or higher 
flow rates. 
 
Principle: 
The underlying principle of UPLC is based on the van Deemter relationship 
which explains the correlation between flow rate and plate height8. The 
van Deemter equation (i) shows that the flow range with the smaller particles is much 
greater in comparison with larger particles for good results 9,10,11,12 
Van Deemter equation, whichis an empirical formula that describes the relationship 
between linear velocity (flow rate) and plate height (HETP or column efficiency). 
H=A+B/v+Cv 
Where; 
A, B and C are constants 
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v is the linear velocity, the carrier gas flow rate. 
*The A term is independent of velocity and represents "eddy" mixing. It is smallest when 
the packed column particles are small and uniform. 
* The B term represents axial diffusion or the natural diffusion tendency of molecules. This 
effect is diminished at high flow rates and so this term is divided by v. 
* The C term is due to kinetic resistance to equilibrium in the separation process.The 
kinetic resistance is the time lag involved in moving from the gas phase to the   packing 
stationary phase and back again.  
Efficiency is proportional to column length and inversely proportional to the 
particle size. Smaller particles provide increased efficiency as well as the ability to work at 
increased linear velocity without a loss of efficiency, providing both resolution and speed. 
Efficiency is the primary separation parameter behind UPLC since it relies on the same 
selectivity and retentivity as HPLC. In the fundamental resolution (Rs) 
 
Chemistry of small particles: 13 
 
The design and development of sub-2 µm particles is a significant challenge, and 
researchers have been active in this area for some time to capitalize on their advantages. A 
commercially available non-porous, high iffiest small particle has poor loading capacity 
and retention due to low surface area. To maintain retention and capacity must use novel 
porous particles that can withstand high pressures. In 2000, hybride of silica & polymeric 
column was introduced which consist of classical sol-gel synthesis that incorporates carbon 
in the form of methyl groups, these columns are mechanically strong. They are highly 
efficient & can be operate at wide range of pH.But, in order to provide the kind of 
enhanced mechanical stability required for UPLC, a second generation bridged ethane 
hybrid (BEH) technology was developed. These 1.7 µm particles derive their enhanced 
mechanical stability by bridging the methyl groups in the silica matrix. 
In order to provide the kind of enhanced mechanical stability required for UPLC, a second 
generation bridge dethane hybrid (BEH) technology was developed.  
 
Instrumentation:  
The UPLC System has been holistically designed to match the performance needs of 
innovative column chemistries with robust hardware, easy-to-use software and specialized 
support services. It consists of: 
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·        Small, pressure-tolerant particles 
·         High-pressure fluidic modules 
·         Minimized system volume 
·         Negligible carryover 
·         Reduced cycle times 
·         Last response detectors 
·         Integrated system software and diagnostics 
UHPLC instrument consists of following : 
A. Sample Injection 
B. UPLC Columns 
C. Detectors 
A. Sample Injection 
In UPLC, sample introduction is critical. Conventional injection valves, either automated or 
manual, are not designed and hardened to work at extreme pressure. To protect the column 
from extreme pressure fluctuations, the injection process must be relatively pulse free and 
the swept volume of the device also needs to be minimal to reduce potential band 
spreading. A fast injection cycle time is needed to fully capitalize on the speed afforded by 
UPLC, which in turn requires a high sample capacity. Low volume injections with minimal 
carryover are also required to increase sensitivity. There are also direct injection 
approaches for biological samples. 
B. UPLC Columns 
Resolution is increased in a 1.7μm particle packed column because efficiency is better. 
Separation of the components of a sample requires a bonded phase that provides both 
retention and selectivity. Four bonded phases are available for UPLC separations: 
(i) ACQUITY UPLCTM BEH C8 (straight chain alkyl columns), 
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(ii) ACQUITY UPLCTM BEH C18 (straight chain alkyl columns), 
(iii) ACQUITY UPLC BEH Shield RP18 (embedded polar group column)  
(iv) ACQUITY UPLC BEH Phenyl (phenyl group tethered to the silyl functionality with a 
C6 alkyl), 
(v) ACQUITY UPLC BEH Phenyl (phenyl group tethered to the silyl functionality with a 
C6 alkyl). 
The binary solvent manager uses two individual serial flow pumps to deliver a 
parallel binary gradient. There are built-in solvent select valves to choose from up to four 
solvents. There is a 15,000-psi pressure limit (about 1000 bar) to take full advantage of the 
sub-2μm particles. The sample manager also incorporates several technology 
advancements. Using pressure assisted sample introduction, low dispersion is maintained 
through the injection process, and a series of pressures transducers facilitate self-
monitoring and diagnostics. It uses needle-in-needle sampling for improved ruggedness and 
needle calibration sensor increases accuracy. Injection cycle time is 25 seconds without a 
wash and 60 sec with a dual wash used to further decrease carry over. A variety of micro 
titer plate formats (deep well, mid height, or vials) can also be accommodated in a 
thermostatically controlled environment. Using the optional sample organizer, the sample 
manager can inject from up to 22 micro titer plates. The sample manager also controls the 
column heater. Column temperatures up to 65°C can be attained. 
C. Detectors 
The detectors are use in UPLC analysis is UV/Visible detector. Detection of analytes is 
conventionally based on absorbance that is concentration sensitivity detectors. In UPLC the 
flow cell volume would have to be reduced to maintain concentration and signal. Based on 
Beer’s Law, smaller volume conventional flow cells would also reduce the path length 
upon which the signal strength depends. A reduction in cross-section means the light path 
is reduced, and transmission drops with increasing noise. Therefore, if a conventional 
HPLC flow cell were used, UPLC sensitivity would be compromised. The ACQUITY 
Tunable UV/Visible detector cell consists of a light guided flow cell equivalent to an 
optical fiber. Light is efficiently transferred down the flow cell in an internal reflectance 
Chapter 1                                                                                                              Introduction 
 
RVS COLLEGE OF PHARMACEUTICAL SCIENCES, SULUR - 641402 Page 15 
 
mode that still maintains a 10mm flow cell path length with a volume of only 500mL. 
Tubing and connections in the system are efficiently routed to maintain low dispersion and 
to take advantage of leak detectors that interact with the software to alert the user to 
potential problems  
1.4 METHOD DEVELOPMENT IN HPLC: 
The steps involved in method development in HPLC are as follows:  
1. Selection of HPLC method and initial system 
2. Selection of optimum conditions  
3. Selectivity optimization 
4. System parameter optimization 
5. Method validation 
 
1. SELECTION OF THE HPLC METHOD AND INITIAL SYSTEM:  
 The choice of the HPLC method is based on the nature of the sample, namely, the 
molecular weight, polarity, ionic character and the solubility parameters, Type of 
Chromatography, Sample preparation, Column selection and column dimensions, Mobile 
phase preparation, Detectors. 
2. SELECTION OF OPTIMUM CONDITIONS: 
This step determines the optimum conditions to adequately retain all analytes. No 
analyte has a capacity factor of less than 0.5. No analyte has a capacity factor of greater 
than 10- 15 Determination of initial conditions. By performing 2 gradients runs differing in 
only the run time. Binarysystem based on either acetonitrile/water or methanol/water 
should be used. 
3. SELECTIVITY OPTIMIZATION: 
To achieve adequate selectivity mobile phase and stationary phase compositions are 
taken in account. To select these, the nature of analytes must be considered. Once the 
analyte types are identified, the relevant optimization parameters may be selected. 
4. SYSTEM PARAMETER  OPTIMIZATION: 
This can be achieved by finding the desired balance between resolution and analysis 
time. Parameters involved include column dimensions, column packing, particle size, flow 
rate. Parameters may be changed without affecting capacity factor or selectivity 
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1.5 VALIDATION 
Validation is the process of establishing documentary evidence demonstrating that 
a procedure, process, or activity carried out in testing and then production maintains the 
desired level of compliance at all stages.  
In the pharmaceutical industry, it is very important that in addition to final testing 
and compliance of products, it is also assured that the process will consistently produce the 
expected results. The desired results are established in terms of specifications for outcome 
of the process.  
Qualification of systems and equipment is therefore a part of the process of 
validation. Validation is a requirement of food, drug and pharmaceutical regulating 
agencies such as the US FDA and their good manufacturing practices guidelines.  
Since a wide variety of procedures, processes, and activities need to be validated, 
the field of validation is divided into a number of subsections including the following: 
 Equipment validation 
 Facilities validation 
 HVAC system validation 
 Cleaning validation 
 Process Validation 
 Analytical method validation 
 Computer system validation 
 Packaging validation 
 Cold chain validation 
1.5.1 International conference on Harmonization (ICH)  
The International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) is a project that brings together the regulatory 
authorities of Europe, Japan and the United States and experts from the pharmaceutical 
industry in the three regions to discuss scientific and technical aspects of pharmaceutical 
product registration. 
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The purpose of ICH is to reduce or eliminate the need to duplicate the testing 
carried out during the research and development of new medicines by recommending ways 
to achieve greater harmonisation in the interpretation and application of technical 
guidelines and requirements for product registration. Harmonisation would lead to a more 
economical use of human, non-human animal and material resources, and the elimination 
of unnecessary delay in the global development and availability of new medicines while 
maintaining safeguards on quality, safety, and efficacy, and regulatory obligations to 
protect public health. 
ICH Method Validation Parameters 18 
 
Table No: 2 ICH characteristics and guidelines. 
Type of analytical 
procedure 
 
IDENTIFICATION TESTING  FOR 
IMPURITIES 
ASSAY 
- dissolution 
(measurement only) 
- content/potency 
characteristics  quantitat.   limit  
Accuracy -  + -  + 
Precision  
    Repeatability 
Interm.Precision 
 
- 
- 
 
 + - 
 + (1) - 
 
 + 
      + (1) 
Specificity (2) +  + +  + 
Detection Limit -  - (3) +  - 
Quantitation Limit -  + -  - 
Linearity -  + -  + 
Range -  + -  + 
- signifies that this characteristic is not normally evaluated 
+ signifies that this characteristic is normally evaluated 
 (1) In cases where reproducibility (see glossary) has been performed, intermediate 
precision is not needed 
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(2)  Lack of specificity of one analytical procedure could be compensated by other 
supporting analytical procedure(s) 
(3) May be needed in some cases 
1.5.2 Method Validation Parameters 
 They have been defined in different working groups of national and international 
committees and are described in literature. The parameters as defined by the ICH and by 
other organization and authors are summarized below. They are  
 
SYSTEM SUITABILITY /SYSTEM PRECISION: 
 
Scope and Definition:  
 
The System suitability/System Precision of an analytical procedure expresses the 
suitability of chromatographic conditions and an evident that the system is giving a precise 
value. 
 
System suitability/System Precision is reported as percentage RSD of replicate 
injections, tailing factor of the major peak and Theoretical plates of standard solution. 
 
System suitability/System Precision of the method was established by injecting five 
standard solutions continuously.  
System Suitability Parameters: 
RSD for 5 replicate injection of standard:  NMT 2.0% 
Tailing Factor                                       :  NMT 2.0 
Theoretical plates                                 :  NLT 2000 
 
SPECIFICITY (Placebo Interference): 
 
Scope And Definition:  
Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present and also to provide an exact result which 
allows an accurate statement on the content or potency of the analyte in a sample. 
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Procedure:  
The Specificity is given by the interference of placebo at the retention time of 
Teneligliptin. 
Solutions of blank, placebo and Teneligliptinat nominal concentration were injected 
to assess the specificity of the analysis. 
 
LINEARITY & RANGE: 
Scope and Definition: 
The ICH defines the linearity of an analytical procedure as the ability (within a 
given range) to obtain test result of variable data which are directly proportional to the 
concentration (amount of analyte). The data variables that can be used for quantitation of 
the analyte are the peak areas, Peak heights or the ratio of peak areas (Heights) of analyte to 
internal standard peak. Quantitation of the analyte depends on it obeying Beer’s law and is 
linear over a concentration range.          
 
Linearity is demonstrated directly by dilution of standard stock solution. For the 
establishment of linearity, 5 concentrations Teneligliptin were used. 
Calculation of Correlation Coefficient: 
Correlation(r) = NΣXY - (ΣX) (ΣY) / Sqrt ([NΣX2 - (ΣX)2][NΣY2 - (ΣY)2])  
 
  N  = Number of value 
               X  = First Score 
              Y  = Second Score 
              ΣXY  = Sum of the product of first and Second Scores 
               ΣX = Sum of First Scores 
               ΣY  = Sum of Second Scores 
               ΣX2 = Sum of square First Scores 
               ΣY2 = Sum of square Second Scores 
 
Slope: Calculation: 
y = mx + c 
Where, x and y are point of the line. 
m is the Slope ; C is the y intercept  
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PRECISION: 
METHOD PRECISION: 
Scope and Definition: 
The precision of an analytical procedure expresses the closeness of agreement 
(degree of scatter) between a series of measurements obtained from the multiple samples of 
the same homogeneous sample under prescribed conditions. 
 
Repeatability: Repeatability is a measure of the precision under the same operating 
conditions over a short interval of time. It is sometimes referred to as intra assay precision. 
Repeatability is assessed using three concentration levels at low, middle and high level of 
working concentration of Teneligliptin.  Three determinations are studied at each level and 
the sample is prepared independently and analyzed. The standard deviation and related 
standard deviation (Co-efficient of variation) for the assay percentage recovery value are 
reported. 
Formulae used for Calculations: 
Average: 
 
                  [X1 + X2 + X3 + X4 +……………+ XN] 
      XA   = -----------------------------------------  
                              N 
Where, 
XA  -  Average 
X  –  Function  
N  – Total number of function (Here N = 6) 
 
Standard Deviation: 
 
[X1- XA]
2 + [X2- XA]+ ……….+[XN- XA]21/2 
Standard Deviation=   -------------------------------------------- 
                          N - 1 
Where, 
X  – Function  
N  – Number of function 
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XA  - Average 
 
Related Standard Deviation: 
            Standard Deviation X 100 
RSD = ------------------------------ 
                       Average 
 
INTERMEDIATE PRECISION: 
 
Scope and Definition:  
Intermediate precision is defined as the variation within the same laboratories with 
respect to the change in the user (Chemist). The extent to which intermediate precision 
needs to be established depends on the circumstances under which the procedure is 
intended to be used. Typical parameters that are investigated include day-to-day variation, 
analyst variation, and equipment variation. Depending on the extent of the study, the use of 
experimental design is encouraged. Experimental design will minimize the number of 
experiments that need to be performed. The final study is reported of standard deviation, 
relative standard deviation (coefficient of variation). 
 
Procedure:  
 
The parameter for the intermediate precision considered here is the variability on 
different days in terms of the same method. Outcome of data is being grouped separately 
Day 1 and Day 2 below to yield to statistical inference. 
Prepared six samples as above and inject separately and standard deviation, relative 
standard deviation (coefficient of variation). 
 
Calculation: 
 
     Sample area x Standard dilution x purity X average net content X 100 
 = ----------------------------------------------------------------------------------------- X 0.6829 
Standard area X Sample dilution X 100 X label claim 
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ACCURACY: 
 
Scope and Definition:  
The accuracy of an analytical procedure express the closeness of agreement 
between the value which is accepted either as a conventional true value or an accepted 
reference value and the value found. 
Accuracy is reported as percentage assay of the known added amount of analyte in the 
sample. 
 
Procedure:  
Accuracy of the method was established by application of the analytical procedure 
to synthetic mixtures of the drug components (placebo) to which known amounts of analyte 
was added and studied at three concentration levels at low, middle and high level of 
working concentration of Teneligliptin. Three determinations are studied at each level and 
the sample is prepared independently and analyzed 
 
ROBUSTNESS: 
 
Scope and Definition:  
The evaluation of robustness should be considered during the development phase 
and depends on the type of procedure under study. It should show the reliability of an 
analysis with respect to deliberate variations in method parameters.  
If measurements are susceptible to variations in analytical conditions, the analytical 
conditions should be suitably controlled or a precautionary statement should be included in 
the procedure.  
In the case of liquid chromatography, examples of typical variations are:  
- Influence of variations of pH in a mobile phase;  
- Influence of variations in mobile phase composition;  
- Different columns (different lots and/or suppliers);  
- Temperature;  
- Flow rate.  
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Depending on the extent of the study, the use of experimental design is encouraged. 
Experimental design will minimize the number of experiments that need to be performed. 
The final study is reported of standard deviation, relative standard deviation (coefficient of 
variation). 
 
 
 
Procedure:  
The parameter for the Robustness study considered here is the deliberate but slight 
change in pH of the buffer used in the mobile phase and Flow rate. Outcome of data is 
being grouped separately to yield to statistical inference. The percentage RSD of assay for 
the   results obtained with Method Precision/Accuracy and the Robustness data is being 
grouped separately to yield to statistical inference. 
 
DETECTION LIMIT: 
 
Several approaches for determining the detection limit are possible, depending on 
whether the procedure is a non-instrumental or instrumental. Approaches other than those 
listed below may be acceptable.  
Based on Visual Evaluation  
Visual evaluation may be used for non-instrumental methods but may also be used 
with instrumental methods. The detection limit is determined by the analysis of samples 
with known concentrations of analyte and by establishing the minimum level at which the 
analyte can be reliably detected.  
 Based on Signal-to-Noise   
This approach can only be applied to analytical procedures which exhibit baseline 
noise.  
Determination of the signal-to-noise ratio is performed by comparing measured 
signals from samples with known low concentrations of analyte with those of blank 
samples and establishing the minimum concentration at which the analyte can be reliably 
detected. A signal-to-noise ratio between 3 or 2:1 is generally considered acceptable for 
estimating the detection limit.  
Based on the Standard Deviation of the Response and the Slope  
The detection limit (DL) may be expressed as:  
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DL = 3.3 σ/  S 
Where, 
 σ = the standard deviation of the response    
S = the slope of the calibration curve  
The slope S may be estimated from the calibration curve of the analyte. The estimate of σ 
may be carried out in a variety of ways,  
For example:   
 
Based on the Standard Deviation of the Blank 
Measurement of the magnitude of analytical background response is performed by 
analyzing an appropriate number of blank samples and calculating the standard deviation of 
these responses.   
Based on the Calibration Curve  
A specific calibration curve should be studied using samples containing an analyte 
in the range of DL. The residual standard deviation of a regression line or the standard 
deviation of y-intercepts of regression lines may be used as the standard deviation.   
 
The detection limit and the method used for determining the detection limit should 
be presented. If DL is determined based on visual evaluation or based on signal to noise 
ratio, the presentation of the relevant chromatograms is considered acceptable for 
justification.  
Several approaches for determining the detection limit are possible, depending on 
whether the procedure is a non-instrumental or instrumental. Approaches other than those 
listed below may be acceptable. 
 
QUANTITATION LIMIT 
Several approaches for determining the quantitation limit are possible, depending 
on whether the procedure is a non-instrumental or instrumental. Approaches other than 
those listed below may be acceptable.  
Based on Visual Evaluation: Visual evaluation may be used for non-instrumental 
methods but may also be used with instrumental methods. The quantitation limit is 
generally determined by the analysis of samples with known concentrations of analyte and 
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by establishing the minimum level at which the analyte can be quantified with acceptable 
accuracy and precision.   
Based on Signal-to-Noise Approach: This approach can only be applied to analytical 
procedures that exhibit baseline noise. Determination of the signal-to-noise ratio is 
performed by comparing measured signals from samples with known low concentrations of 
analyte with those of blank samples and by establishing the minimum concentration at 
which the analyte can be reliably quantified. A typical signal-to-noise ratio is 10:1.   
 Based on the Standard Deviation of the Response and the Slope 
 The quantitation limit (QL) may be expressed as:  
QL = 10 σ  /S  
Where, 
 σ = the standard deviation of the response    
S = the slope of the calibration curve  
The slope S may be estimated from the calibration curve of the analyte. The estimate of σ 
may be carried out in a variety of ways  
for example:   
Based on Standard Deviation of the Blank  
Measurement of the magnitude of analytical background response is performed by 
analyzing an appropriate number of blank samples and calculating the standard deviation of 
these responses.   
Based on the Calibration Curve: A specific calibration curve should be studied using 
samples, containing an analyte in the range of QL. The residual standard deviation of a 
regression line or the standard deviation of y-intercepts of regression lines may be used as 
the standard deviation. 
The quantitation limit and the method used for determining the quantitation limit 
should be presented. The limit should be subsequently validated by the analysis of a 
suitable number of samples known to be near or prepared at the quantitation limit. 
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LITERATURE REVIEW 
Sohan S. Chitlange31 et al, has been developed a simple, accurate, precise and 
economical HPLC and UV method has been developed and validated for the estimation 
of teneligliptin hydrobromide hydrate (THH) in bulk and tablet dosage form. Isocratic 
elution at the flow rate of 1.0 ml/min was employed on a Kromasil 100-5-C8 column at 
ambient temperature. The mobile phase consisted of Methanol: 0.025M phosphate buffer 
pH adjusted to 3 with o-phosphoric acid (60:40 v/v). The detection wavelength was at 
254nm. Linearity was observed in the concentration range of 10-100 µg/ml. The retention 
time for Teneligliptin was 4.14 min. In stability testing, teneligliptin was found 
susceptible to alkali hydrolysis and oxidatative degradation. Because the method could 
effectively separate the drug from its degradation products, it can be used as a stability 
indicating method. First order derivative UV spectrophotometric method was also 
developed using methanol as solvent at analytical λ 261.0 nm. Beer’s law was obeyed in 
the concentration range of 5-50 µg/ml and r2 =0.9996. The proposed methods were 
validated according to the ICH guidelines. Both the developed methods are accurate and 
precise and can be used for routine quality control analysis of Teneligliptin in bulk and 
pharmaceutical formulation. In case of HPLC as well resolved peak is obtained for 
Teneligliptin after degradation, method is also suitable for stability studies. 
 
Vinutha Kommineni 32et al, has been developed A new stability indicating RP HPLC 
method has been developed and validated for simultaneous estimation of Metformin 
Hydrochloride and Teneligliptin in bulk and dosage forms. The method involves 
separation on YMC C18column (150mm x 4.6mm x5µm particle size). The optimized 
mobile phase consists of Phosphate buffer (pH 3) and Acetonitrile (80:20v/v) with a flow 
rate of 0.8ml/min and UV detection at 220mn. Retention time was 2.138min (Metformin 
Hydrochloride), 2.943min (Teneligliptin), 5.075 Pioglitazone. Linearity range was 9.98-
600ug/ml (Metformin Hydrochloride), 0.51-24ug/ml (Teneligliptin). Accuracy was in the 
range of 99.41-100.74% for both drugs. Precision was 0.8% and 0.9% for Metformin 
Hydrochloride and Teneligliptin. LOD and LOQ are 0.72ug/ml and 2.40ug/ml for 
Metformin Hydrochloride, 0.15ug/ml and 0.51ug/ml for Teneligliptin. The method 
developed is sensitive, accurate and precise. Retention time and run time were also less 
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and hence the method is economical. When applied for tablet assay, drug content was 
within 99.89-100.74 % of labeled content. Forced degradation studies indicated the 
suitability of the method for stability studies.  
 
Shailesh V. Luhar33 et al, worked on Simultaneous Estimation of Teneligliptin 
Hydrobromide Hydrate and its Degradation Product by RP-HPLC Method. A simple, 
rapid, precise and accurate reversed-phase stability-indicating RP-HPLC method was 
developed and validated for the simultaneous determination of Teneligliptin 
hydrobromide hydrate in marketed formulation (tablets). The method has shown adequate 
separation for Teneligliptin hydrobromide from its associated main impurities and their 
degradation products. Separation was achieved on a Shisedo C18column, 5μm, 250mm × 
4.6 mm i.e. column using a mobile phase consisting of Acetonitrile:Methanol: Water 
(30:40: 30 % v/v/v) at a flow rate of 1.0ml/min and UV detection at 246nm. The drugs 
are subjected to acid hydrolysis, alkaline hydrolysis, oxidative degradation and thermal 
degradation to apply force degradation testing. The linearity of the proposed method was 
investigated in the range of 50-300μg/ml (r2= 0.9996). The limit of detection was2.78 
μg/ml and the limit of quantification was 8.45 μg/ml 
 
Atul T. Hemke34 etal, reported work on HPLC and UV-spectrophotometric estimation of 
teneligliptin from tablet dosage form. The present work proposed precise, accurate and 
validated HPLC and UV-spectrophotometric methods for estimation of Teneligliptin 
from its tablet dosage form. The UV-spectrophotometric estimation includes Calibration 
curve, Area under curve (AUC) and First order derivative method based on measurement 
of absorbance at a selected wavelengths using UV-visible spectrophotometer with 1cm 
matched quartz cell and distilled water as a solvent. All UV-spectrophotometric methods 
obeyed Beer’s-lambert’s law in the concentration range of 10-70μg/mL, with correlation 
coefficient value less than 1. The chromatographic separation was achieved by isocratic 
mode with a mixture of methanol: phosphate buffer (pH 7.2) in the ratio of 70:30 v/v as 
the mobile phase using Shodex C18 column as stationary phase at flow rate of 1mL/min 
and detection wavelength of 244nm. The retention time was found to be 5.753min. The 
percent amount of drug estimated by all developed methods was nearly 100%, found to 
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be in good agreement with label claim of marketed tablet formulation. The recovery 
study was carried out at five different levels and results were found to be satisfactory. 
The validation parameters like accuracy, precision, ruggedness, linearity and range were 
studied for all the developed methods and were found to be within limits. Stress testing 
under various conditions such as pH (acid/base), temperature, light, oxidation, humidity 
was carried out and % undegraded drug was calculated 
 
T. N. V. Ganesh Kumar35 et al, worked on Method development, validation, and 
stability studies of teneligliptin by RP-HPLC and identification of degradation products 
by UPLC tandem mass spectroscopy. Background: Teneligliptin is a new FDA approved 
drug for treating Diabetes Mellitus. There are no reported evidences for their identified 
degradation products and their effects on humans. Methods: A simple and new stability 
indicating RP-HPLC method was developed and validated for identification of 
Teneligliptin and its degradants on Kromasil 100- 5C18 (250×4.6mm, 5μm) column 
using pH 6.0 phosphate buffer and acetonitrile (60:40 v/v) as a mobile phase in isocratic 
mode of elution at a flow rate of 1.0 mL/min. The column effluents were monitored by a 
variable wavelength UV detector at 246 nm. The method was validated as per ICH 
guidelines. Forced degradation studies of Teneligliptin were carried out under acidic, 
basic, neutral (peroxide), photo and thermal conditions for 48 hours at room temperature. 
The degradation products were identified by HPLC and characterized by UPLC with 
tandem mass spectroscopy (LC/MS/MS). Results: UPLC MS/MS data shown major 
peaks, observed at 375.72, 354.30, 310.30, 214.19, 155.65, 138.08 and 136.18 m/z. 
Conclusion: Degradation was observed in base, peroxide and thermal stressed samples, 
but not in acid and photolytic stressed samples.  
 
M.Chandana36 et al, worked on analytical method development and validation of 
teniligliptin in phrmaceutical dosage form by RP-HPLC method. A reverse phase liquid 
chromatography (RP-HPLC) method has been developed and subsequently validated for 
the determination of Teneligliptin in Bulk and its pharmaceutical formulation. Separation 
was achieved with a Zodiac C18 column(250×4.6 mm I.D., 5μm particle size , methanol:  
acetonitrile (90:10) v/v  as mobile phase at a flow rate  of 1.0 ml/min , pH 5.2 adjusted 
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with 0.10% orthophosphoric acid and the Column temperature was maintained at 25°C. 
UV detection was performed at 235 nm and sample temperature was maintained at 5°C 
with a run time of 10min . The method is simple, rapid, and selective. The described 
method of Teneligliptin  is linear over a range of 25 to 150μg/ml with correlation 
coefficient of 0.9991 respectively .The method precision for the determination of assay 
was below 2.0% RSD. The method enables accurate, precise, and rapid analysis of 
Teneligliptin . It can be conveniently adopted for routine quality control analysis of Bulk 
and pharmaceutical formulations. 
 
Vishnu C. Shinde37 et al, worked on Development and validation of UV 
spectrophotometric method and high performance thin layer chromatographic (HPTLC) 
method for estimation of teneligliptin hydrobromide in pharmaceutical preparation . 
Simple, rapid, sensitive, precise and speciﬁc UV spectrophotometric and High-
performance thin layer chromatographic (HPTLC) methods for the determination of 
Teneligliptin Hydrobromide both in bulk drug and pharmaceutical dosage form were 
developed and validated. In UV spectrophotometric method, the solutions of 
Teneligliptin HBr were prepared in water. The standard solution of Teneligliptin HBr 
showed maximum absorption at wavelength 243.5 nm. The drug obeyed Beer–Lambert’s 
law in the concentration range of 10– 90 µg/mL with coefficient of correlation (r2) of 
0.999. For HPTLC method, the method employed aluminium plates precoated with silica 
gel G60 F254 as the stationary phase. The solvent system consisted of toluene: 
chloroform: ethanol: diethyl amine in the proportion of 4:4:1:1, v/v/v/v. This solvent 
system was found to give compact spots for Teneligliptin HBr with Rf value 0.16 ± 0.01. 
Densitometric analysis of Teneligliptin HBr was carried out in the absorbance mode at 
254 nm. Linear regression analysis showed good linearity (r2 =0.998) with respect to 
peak area in the concentration range of 100–600 ng/spot. The developed methods were 
validated as per the ICH guidelines. Statistical analysis proved that the methods are 
repeatable and speciﬁc for the estimation of the said drug. These methods can be adopted 
in routine assay analysis of Teneligliptin HBr in bulk or tablet dosage form. 
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Raja Haranadha Babu Chunduri 38 et al, worked development and validation of LC-
MS/MS method for quantification of teneligliptin in human plasma and its application to 
a pharmacokinetic study. A selective, sensitive and rapid liquid chromatographic method 
with electro spray ionization tandem mass spectrometric detection has been developed 
and validated for quantification of teneligliptin in human plasma using repaglinide as 
internal standard (IS). The analytes and IS were extracted from 50 µL of plasma by 
liquid-liquid extraction technique using methyl tert - butyl ether which offers high 
sensitivity, wide linearity without interferences form endogenous matrix components. In 
a short chromatographic run of 1.50 min run time, separation was achieved on a Hypersil 
Gold C18 column using a mobile phase composed of 0.1% formic acid in Milli-Q 
water/0.1% formic acid in acetonitrile in gradient elution mode. The quantification of 
teneligliptin was performed in a positive electro spray ionization mode and multiple 
reaction monitoring (MRM). Response was a linear function of concentration in the 
ranges of 0.1 to 4000 ng/mL for teneligliptin with r2> 0.99. The intra- and inter-day 
precision and accuracy results were below 15% and acceptable as per Food and Drug 
Administration (FDA) guidelines. Stability of teneligliptin was established in a battery of 
stability studies, i.e. bench top, auto sampler and long term storage stability as well as 
freeze thaw cycles. The validated method can be used as a routine method to support 
pharmacokinetic studies.   
 
Ruchi P Pandya39 et al, worked on development and validation of RP-HPLC method for 
simultaneous Estimation of teneligliptin hemipentahydrobromide hydrate and 
Metformin hydrochloride in their combined tablet dosage form. A simple, rapid and 
precise reverse phase high performance liquid chromatographic method has been 
developed for simultaneous estimation of Teneligliptin hemipentahydrobromide hydrate 
and Metformin Hydrochloride in their combine tablet dosage form. Chromatography was 
0.025M Dipotassium hydrogen phosphate buffer:Acetonitrile (75:25 v/v) as a mobile 
phase. The detection was carried out at 238 nm with a flow rate of 1.0 mL/min. The 
retention times were 2.167 and 6.033 minutes for Metformin Hydrochloride and 
Teneligliptin hemipentahydrobromide hydrate, respectively. Proposed method was 
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validated as per ICH guidelines for linearity, accuracy, precision, specificity and 
robustness for estimation of Teneligliptin hemipenta hydrobromide hydrate and 
Metformin Hydrochloride in their combined Tablet dosage form and results were found 
to be satisfactory. The linearity of the method was excellent over a concentration range 5 
to 15 μg/mL for Teneligliptin hemipenta hydr bromide hydrate and 125 to 375 μg/mL for 
Metformin Hydrochloride. The correlation coefficient was 0.997 and 0.999 for 
Teneligliptin hemipenta hydrobromide hydrate and Metformin Hydrochloride, 
respectively. The limit of detection was 0.771 μg/mL and 2.959 μg/mL for Teneligliptin 
hemipenta hydrobromide hydrate and Metformin Hydrochloride, respectively. The limit 
of quantitation was 2.336 μg/mL and 8.967 μg/mL for Teneligliptin hemipenta 
hydrobromide hydrate and Metformin Hydrochloride, respectively. The relative standard 
deviation values for repeatability, intraday precision and interday precision studies were 
less than 2 % and % recovery was between 98 % to 102 % for both drugs. So the 
proposed method was found to be suitable as per ICH Guidelines Q2(R1) for the routine 
estimation of Teneligliptin hemipentahydrobromide hydrate and Metformin 
Hydrochloride in their Combined Tablet dosage form. 
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DRUG PROFILE 
TENELIGLIPTIN19-29: 
Teneligliptin is a pharmaceutical drug for the treatment of type 2 diabetes 
mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 
inhibitors or "gliptins". Teneligliptin HBr hydrate is a novel, potent, peptidomimetic, and 
long-acting DPP-4 inhibitor which got approval for the treatment of T2DM in Japan and 
Argentina (2012), Korea (2014) and India (2015) Teneligliptin drug inhibit the enzyme 
dipeptidyl peptidase-4 which degrades incretin, a hormone adjusting blood glucose level. 
Brand name: Tenelia 
Chemical IUPAC Name:  {(2S,4S)-4-[4-(3-Methyl-1-phenyl-1H-pyrazol-5-yl)-1             
                                           - piperazinyl]-2-pyrrolidinyl}(1,3-thiazolidin-3-yl)methanone 
 
Molecular formula: C22H30N6OS 
Chemical Structure: 
 
Molecular formula  :  C22H30N6OS  
Molecular weight    :  426.58 
Description              :  White powder 
Boiling Point           : 661.189°C at 760 mmHg 
Melting point           : 202 °C 
Solubility                  : 10 mM in DMSO and in methanol  
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Category                 : Anti-diabetic 
                  Metabolite              : inactive Metabolites. 
Bioavailability        : 63-85 % 
Protein Binding      : 78-80 % 
Elimination 
Clearance                : Feaces (46.5 %) and urine (45.4 %)    
T1/2                                         : 26.9 hours 
CLINICAL PHARMACOLOGY: 
 Mechanism of Action: Teneligliptin inhibited human dipeptidyl peptidase-4 (DPP-4) 
enzyme activity with the IC50 =1nM, more than 150 fold selectivity against DPP-8 and 
DPP-9 which suggested little off-target skin lesion side effect. By DPP-4 inhibtion,    
Teneligliptin prevented the degradation of incretins GLP-1, GIP and promoted insulin 
release which prevented blood glucose increase after food intake with little hypoglycemia 
risk during lifetime taken. 
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Pharmacokinetics 
Teneligliptin is rapidly absorbed in healthy volunteers after a single radiolabeled 20 mg 
dose, with maximum plasma concentrations attained in 1.33 hr. The drug is 78% - 80% 
bound to plasma proteins. An overview of Teneligliptin pharmacokinetics is mentioned in 
Table 3. In humans, Teneligliptin is primarily metabolized by cytochrome P450 (CYP) 
3A4 & flavin monooxygenases (FMO) 1 and 3 to several metabolites of unknown 
biological activity. In vitro, Teneligliptin is a weak inhibitor of CYP2D6, CYP3A4 and 
FMO, but shows no inhibitory effect on CYP1A2, CYP2A6, CYP2B6, CYP2C8, 
CYP2C8/9, CYP2C19 and CYP2E1. Teneligliptin does not induce CYP3A4 or CYP1A2 
There were no clinically relevant drug-drug interactions when Teneligliptin was co-
administered with Ketoconazole (a potent CYP3A4 and P-glycoprotein inhibitor) 
Metformin or Canagliflozin in healthy volunteers. No clinically relevant effects on the 
pharmacokinetics of Teneligliptin were observed when it was coadministered with 
Glimepiride or Pioglitazone. Teneligliptin follows dual mode of excretion i.e. renal & 
hepatic. At least 90% of the radiolabeled dose of Teneligliptin was excreted within 216 h, 
with 45.4% excreted in the urine and 46.5% excreted in the faeces  Approximately 21% 
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of Teneligliptin is excreted in the urine as unchanged drug. Teneligliptin has long half-
life of 26.9 hours which offers convenient once a day administration  
CLINICAL STUDIES: 
Criteria 
Inclusion Criteria: 
 Patients who has been receiving a stable dose and regimen of insulin over 12 weeks 
before administration of investigational drug 
 Patients who are under dietary management and taking therapeutic exercise for diabetes 
over 12 weeks before administration of investigational drug 
 Patients whose HbA1c is between 7.5% and 10.5% 
 Patients who were not administered diabetes therapeutic drugs prohibited for concomitant 
use within 12 weeks before administration of investigational drug. 
 
 
Exclusion Criteria: 
 Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or 
secondary diabetes (Cushing disease, acromegaly, etc) 
 Patients who are accepting treatments of arrhythmias 
 Patients with serious diabetic complications 
 Patients who are the excessive alcohol addicts 
 Patients with severe hepatic disorder or severe renal disorder. 
 Patients who are pregnant, lactating, and probably pregnant patients, and patients who 
cannot agree to contraception 
 
Indications and usage: 
Teneligliptin is used as a monotherapy, in addition to diet and exercise, to reduce 
high blood sugar levels in patients with type 2 diabetes mellitus.  
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Contradictions: 
 To  any allergic reactions (itch, rash, etc.) to any medicines, ketosis, diabetic coma 
or precoma stage, type 1 diabetes mellitus, infection, in pre/post operative period, 
trauma. 
 In  pregnant conditions or breastfeeding. 
 If you are taking any other medicinal products. (Some medicines may interact to 
enhance or diminish medicinal effects. Beware of over-the-counter medicines and 
dietary supplements as well as other prescription medicines.) 
Dose: 
 In general, for adults, take 1 tablet (20 mg of teneligliptin) at a time, once a day. If 
the effect is insufficient, the dose may be increased up to 2 tablets (40 mg) at a time, 
once a day. Strictly follow the instructions. 
 If you miss a dose, take a dose as soon as possible. If it is almost time for the next 
dose, skip the missed dose and continue your regular dosing schedule. You should 
never take two doses at one time. 
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AIM & OBJECTIVE OF PRESENT WORK 
 
 Teneligliptin is a pharmaceutical drug for the treatment of type 2 diabetes 
mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 
inhibitors or "gliptins". Teneligliptin HBr hydrate is a novel, potent, peptidomimetic, and 
long-acting DPP-4 inhibitor which got approval for the treatment of T2DM in Japan and 
Argentina (2012), Korea (2014) and India (2015) Teneligliptin drug inhibit the enzyme 
dipeptidyl peptidase-4 which degrades incretin, a hormone adjusting blood glucose level. 
  Till date only few analytical methods in RP- HPLC have been reported for the 
determination of Teneligliptin in pharmaceutical dosage forms. Existing literature reveals 
that analytical methods like HPLC,UV and HPTLC methods were available but no UHPLC 
Methods were reported. Therefore, the present study has been undertaken in order to develop 
a new, simple, rapid, efficient and reproducible RP-UHPLC method for the analysis of 
Teneligliptin tablets. 
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Materials used: 
 1-Octane sulfonic acid Sodium salt  
HPLC Grade 
Maker: RANKEM 
 Acetonitrile 
HPLC Grade 
Maker: RANKEM 
 Ortho-Phosphoric Acid 
AR Grade 
Maker: RANKEM 
 Methanol 
HPLC Grade 
 HPLC Grade Water 
 
 
METHOD USED FOR ASSAY OF TENELIGLIPTIN TABLETS 
STRENGTH: 20 mg 
Chromatographic parameters: 
Column  : Phenomenex Luna C18, 50×3.0mm, 3μm particle size 
Flow rate  : 0.5 mL/min 
Run Time   : 3 minutes 
Wavelength              : 245nm 
Temperature              : Ambient 
Injection Volume : 2μL  
Mobile phase composition: pH 3.5 Buffer: Acetonitrile (50:50v/v)   
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Preparation of pH 3.5 Buffer solution: Weigh and dissolve 1.00 g of 1-Octane sulfonic 
acid Sodium salt to 1000 ml of water. Adjust pH of solution to 3.5with dilute orthophosphoric 
acid. 
Preparation of mobile phase: 
1. Mix pH 3.5 Buffer solution and acetonitrile in the ratio 50:50(v/v) 
2. Filter through 0.45µm membrane filter and degas for about 10min. 
Note: Do not use the mobile phase preparation beyond 2days of bench top or 5days in 
refrigerator. 
Diluent: Use mobile phase as diluent. 
Preparation of standard stock solution:  
 Weigh accurately and transfer about 75 mg Teneligliptin Hydrobromide working 
standard which is equivalent to about 50 mg of Teneligliptin into a 100ml volumetric 
flask, add about 35ml of diluent, sonicate to dissolve the material completely, dilute to 
volume with diluent and mix. 
Preparation of standard solution: 
1. Pipette 5ml of the above solution into a 25ml volumetric flask, dilute to volume 
with diluent and mix. 
2. Filter through 0.45µm filter. 
Note: Do not use the standard preparation beyond 2days in refrigerator. 
Test preparation: 
1. Weigh and crush not less than 20 tablets using mortar and pestle. 
2. Weigh and transfer the tablet powder equivalent to about 10 mg of Teneligliptin 
into a 100ml volumetric flask, add about 75ml of diluent, sonicate for 30minutes 
with intermediate shaking and dilute to volume with diluent. 
3. Centrifuge a portion of above solution at 2500rpm for about 10minutes by using 
centrifuge tubes with caps. 
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4. From the above supernatant solution is used. 
5. Filter through 0.45µm filter. 
6. Note: Do not use the test preparation beyond 2days on bench top or 5days in 
refrigerator. 
System suitability: 
1. Inject about 10 µL portion of standard solution into the chromatographic system 
and measure the response of major peak. 
2. The tailing factor for Teneligliptin peak should be  NMT 2.0 
3. The RSD for the area of Teneligliptin peak obtained from the 5 replicates 
injections of standard preparation should be NMT 2.0%. 
Procedure: 
 Inject about 10 µL portion of diluent and test preparation into the chromatograph, 
record the chromatogram and measure the response of major peak. 
Calculations: 
           Sample area x Standard dilution x purity x average weight x 100 X 0.6829 
  ------------------------------------------------------------------------------------- 
Standard area x Sample dilution x 100 x label claim 
 
Where: 0.6829 is conversion factor  
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ASSAY METHOD DEVELOPMENT AND OPTIMISATION 
1. Detection method & Selection of wavelength: 
  Known concentration of Teneligliptin working standard was taken and dissolved 
in solvent such that the standard solution contains about 10ppm. Placebo and blank 
solutions were also prepared. All these solutions were scanned between 200 to 400nm 
using UV-Visible spectrophotometer.From the UV spectrum at the drug shows good 
absorbance 245 nm.  
  After reviewing the chromatograms and peak purity chromatograms a wavelength 
of 245 is selected as the optimum wavelength for this drug. 
2. Selection of column: 
As the Method is UHPLC various columns cannot be selected as the method is 
highly accurate, hence a particular UHPLC column is selected i.e., Phenomenex Luna 
C18(2) ; 3µm ; (3*50mm) which gave good peak shape, retention time, tailing 
factor,column efficiency. Hence Phenomenex column is selected 
3. Optimization of mobile phase: 
  On the basis of retention propperty study results of the drug and reviewing the 
results“1-Octane sulfonic acid Sodium salt” is decided as the buffer preparation to be used. 
 Selection of pH of the buffer:  
  ‘pH’ plays very an important role in achieving the chromatographic separation as 
it controls the elution properties by controlling ionizationcharacteristics.  
By altering the pH of the mobile phase different trials were carried out and finally 
optimized pH was found to be 3.5 
At pH 3.5 peak shape, peak tailing and theoretical plate count was found to be 
satisfactory and hence 3.5 is decided as the pH of the Buffer. 
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Mobile phase composition:  
  Many trials on composition of Buffer and Acetonitrile were made to decide the 
ultimate composition of the mobile phase.  
After reviewing many trials good peak shape, retention time, tailing factor, theoretical 
plates are obtained with the mobile phase composition Buffer: ACN (50:50). Hence it 
was finalized.  
4. Selection of flow rate: 
  Flow rate selection is done depending on the retention time, peak symmetry, 
hence many trials were made to decide the flow rate and 0.5 ml /min was found to be 
acceptable as the peak is sharp. Hence   0.5 ml/ min flow rate was selected for this project 
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METHOD DEVELOPMENT PHASE CHROMATOGRAMS: 
TRIAL I: 
Chromatographic Conditions: 
Mobile phase : Water : Methanol (80 :20% v/v) 
Column : Phenomenex Luna C18 (50 mm x 3.0 mm, 3.0µm) 
Flow rate : 0.5 ml 
Wavelength : 245 nm 
Column Temperature : Ambient 
Injection Volume : 2µl 
 
 
Observation: From the above chromatogram it was observed that the peak is broad and 
shows tailing. 
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TRIAL II: 
Chromatographic Conditions: 
Mobile phase : Water : ACN (70:30 % v/v) 
Column : Phenomenex Luna C18 (50 mm x 3.0 mm, 3.0µm) 
Flow rate : 0.5 ml 
Wavelength : 245 nm 
Column Temperature : Ambient 
Injection Volume : 2µl 
 
 
Observation: From the above chromatogram it was observed that the peak shape and  
tailing factor  is not upto the aim of the project 
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TRIAL III: 
Chromatographic Conditions: 
Mobile phase : ACN: Phosphate buffer pH 6.0  (30:70% v/v) 
Column : Phenomenex Luna C18 (50 mm x 3.0 mm, 3.0µm) 
Flow rate : 0.5 ml 
Wavelength : 245 nm 
Column Temperature : Ambient 
Injection Volume : 2µl 
 
 
Observation: From the above chromatogram it was observed that the peak shape is not 
sharp and retention time is not upto the aim of the project. 
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TRIAL IV: 
Chromatographic Conditions: 
Mobile phase : ACN: Phosphate buffer pH 4.5 (40 :60 % v/v) 
Column : Phenomenex Luna C18 (50 mm x 3.0 mm, 3.0µm) 
Flow rate : 0.5 ml 
Wavelength : 245 nm 
Column Temperature : Ambient 
Injection Volume : 2µl 
 
 
Observation: From the above chromatogram it was observed that the peak shape is not 
sharp and retention time is not upto the aim of the project 
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TRIAL V: 
Chromatographic Conditions: 
Mobile phase : Methanol: Phosphate buffer pH 4.0 (50:50 % v/v) 
Column : Phenomenex Luna C18 (50 mm x 3.0 mm, 3.0µm) 
Flow rate : 0.5 ml 
Wavelength : 245 nm 
Column Temperature : Ambient 
Injection Volume : 2µl 
 
 
Observation: From the above chromatogram it was observed that theobtained Retention 
time, peak shape, tailing factor, theoretical plates is not upto the aim of the project 
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TRIAL VI: 
Chromatographic Conditions: 
Mobile phase : ACN: 1-Hexane sulfonic acid Sodium salt pH 3.5(50:50 % v/v) 
Column : Phenomenex Luna C18 (50 mm x 3.0 mm, 3.0µm) 
Flow rate : 0.5 ml 
Wavelength : 245 nm 
Column Temperature : Ambient 
Injection Volume : 2µl 
 
 
Observation: From the above chromatogram it was observed that the obtained Retention 
time, peak shape, tailing factor, theoretical plates is not upto the aim of the project. 
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TRIAL VII: 
Chromatographic Conditions: 
Mobile phase 
: 
Methanol: 1-Octane sulfonic acid Sodium salt pH 3.5(60:40% 
v/v) 
Column : Phenomenex Luna C18 (50 mm x 3.0 mm, 3.0µm) 
Flow rate : 0.5 ml 
Wavelength : 245 nm 
Column Temperature : Ambient 
Injection Volume : 2µl 
 
 
Observation: From the above chromatogram it was observed that the obtained Retention 
time, peak shape, tailing factor, theoretical plates is not upto the aim of the project. 
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TRIAL VIII:  
Chromatographic Conditions: 
Mobile phase : ACN: 1-Octane sulfonic acid Sodium salt pH 3.5 (50:50 % v/v) 
Column : Phenomenex Luna C18 (50 mm x 3.0 mm, 3.0µm) 
Flow rate : 0.5 ml 
Wavelength : 245 nm 
Column Temperature : Ambient 
Injection Volume : 2µl 
 
 
Observation: From the above chromatogram it was observed that the obtained Retention 
time, peak shape, tailing factor, theoretical plates,satisfies the aim of the project. 
Hence this is optimized chromatographic conditions. 
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Optimized Chromatographic Conditions  for Teneligliptin was 
Mobile phase : Buffer :ACN(50:50 v/v) 
Buffer : 
1.0 g of 1-Octane sulfonic acid Sodium salt to 1000 ml of 
water. Adjust pH of solution to 3.5with dilute 
orthophosphoric acid 
pH : 3.5 
Column : Phenomenex Luna C18 (50 mm x 3.0mm, 3.0µm) 
Flow rate : 0.5 ml/min 
Wavelength : 245 nm 
Column Temperature : Ambient 
Injection Volume : 2µl 
Run time :  3 minutes 
 
 
SYSTEM SUITABILITY: 
1. Inject about 2 µL portion of standard solution into the chromatographic system 
five injections and measure the response of major peak. 
2. The tailing factor for Teneligliptin peak should be  NMT2.0 
The RSD for the area of Teneligliptin peak obtained from the 5replicates injections of 
standard preparation should be NMT 2.0%. 
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Table No: 1 
Injection 
Retention 
time 
Area 
Theoretical 
plates 
Tailing 
factor 
BLANK 0.0 0 0 0.00 
STANDARD-1 1.02 1361.354 2125 1.05 
STANDARD-2 1.02 1365.524 2123 1.05 
STANDARD-3 1.02 1364.443 2124 1.05 
STANDARD-4 1.02 1363.557 2126 1.06 
STANDARD-5 1.02 1364.756 2125 1.06 
AVERAGE - 1363.927 - - 
STDEV - 1.602 - - 
%RSD - 0.1 - - 
 
Fixed chromatographic conditions are as follows: 
Instrument     : UHPLC_AGILENT_1220 INFINITY LCwith UV detector and auto                                                                                                                                   
sampler. 
Column        : Phenomenex Luna C18, 50×3.0mm, 3μm particle size.   
Flow rate        : 0.5 mL/min 
Wavelength     : 245nm 
Temperature        : Ambient 
Injection Volume  : 2μL  
Mobile phase composition: pH 3.5 Buffer: Acetonitrile (50:50V/v)   
 
Chapter-4(b)                                                                                                      Method Validation 
 
RVS COLLEGE OF PHARMACEUTICAL SCIENCES , SULUR - 641402 Page53 
 
ASSAY METHOD VALIDATION 
 
1. PRECISION 
 
Precision covers 
 System precision 
 Method precision 
 
System Precision 
Six replicate injection of homogeneous standard solution indicate performance of 
UHPLC instrument underchromatographic conditions. Six sample preparations were 
prepared and injected at the nominal concentration level i.e., 100 ppm. The results 
obtained are as shown in Table-2 
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SYSTEM PRECISION 
Table No: 2  
 
Since the %RSD was found to be below 2%, the system precision parameter passed. 
 
Method precision/Repeatability: 
This is determined by preparing 9 samples of homogeneous sample mixture at 
 3 Concentrations and  3 replicates each and the results obtained are as shown in Table-3 
and chromatogram follows. 
 
 
 
Sample ID 
Rt 
(min) 
Area 
Theoretical 
Plates (N) 
Tailing Factor 
SYSTEM 
PRECISION-1 
1.02 1361.254 2125 1.05 
SYSTEM 
PRECISION-2 
1.02 1365.746 2153 1.03 
SYSTEM 
PRECISION-3 
1.03 1363.547 2145 1.06 
SYSTEM 
PRECISION-4 
1.02 1364.253 2136 1.05 
SYSTEM 
PRECISION-5 
1.02 1366.215 2162 1.05 
SYSTEM 
PRECISION-6 
1.02 1365.158 2135 1.06 
AVERAGE 3.964 1364.362 2143 1.05 
STDEV - 1.807 - - 
%RSD - 0.132 - - 
LIMITS NMT 1% NMT 2% NLT 2000 NMT 2 
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METHOD PRECISION 
Table No: 3 
 
 
ACCURACY: 
 
Dosage blends of Teneligliptin tablets was spiked with 10%,20%,and 30 % of 
known amount of Standard and to obtain110%, 120% and 130% with respect to labeled 
amount of drug in the formulation. It has been prepared in such a way that the average 
weight of tablet is kept constant and the weight of API was varied. Test solution was 
injected and the assay was performed as per the test method. From this “%Recovery” and 
mg recovered were calculated. The results are as shown in the following Table No: 4 and 
follows chromatograms.  
 
 
Test Preparation Injection Area %Assay 
Low Level 
1 1090.24 99.35 
2 1090.05 99.05 
3 1090.34 99.82 
Middle Level 
1 1364.28 99.76 
2 1364.01 99.78 
3 1364.20 99.28 
High Level 
1 1635.00 99.43 
2 1634.56 99.64 
3 1634.19 99.17 
Mean for Assay 99.48 
Standard Deviation 0.285 
%RSD 0.286 
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ACCURACY 
 
Table No: 4 
 
Acceptance criteria here are that the % Recovery calculated should be between 98% to 
102%. Here percentage Recovery is calculated using the above formula. 
LINEARITY 
                        Linearity has been demonstrated in the range of 50-150% of target 
concentration of the assay. Five series of standard solutions in the above concentration 
range were injected in duplicate. Standard solution in concentrations of 50, 70, 100, 130, 
150 ppm were prepared and injected and the peaks areas and other statistical data are given 
in Table No: 5. A calibration curve was determined for the drug independently by plotting 
Spiked Level API Added (mg) API Recovered (mg) %Recovery 
110 % 
2.0001 
1.9917 99.58 
110 % 1.9919 99.59 
110 % 1.9943 99.71 
120% 
4.0002 
3.9804 99.50 
120% 3.9925 99.81 
120 % 3.9943 99.85 
130 % 
6.0004 
6.0040 100.06 
130% 5.9902 99.83 
130 % 5.9819 99.69 
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the peak areas obtained against concentrations (in percentage). There exists a linear 
relationship in the two graphs for the two concentration ranges which are prepared. From 
the data obtained correlation coefficient, Y- intercept and slope were calculated to provide 
mathematical estimates of the degree of linearity. Chromatograms are as shown below,  
From the chromatograms, average area of Teneligliptin is calculated and is tabulated as 
follows. From this response values a linear curve is obtained as shown in below. 
Table No: 5 
LINEARITY CURVE FOR TENELIGLIPTIN 
API Percentage 
 50% 70% 100% 130% 150% 
Trial-1 697.839 940.541 1362.465 1770.863 2049.276 
Trial-2 697.648 940.374 1362.337 1770.148 2049.443 
Average 697.744 940.458 1362.401 1770.506 2049.360 
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SPECIFICITY: 
Placebo Interference: 
Assay was performed on the weight of the placebo equivalent to the amount present in the 
test preparation. Chromatogram of the placebo did not show any peak at the Retention time 
of the analyte peak. So interference of the placebo is considered significant. 
Chromatograms are as follows, 
Table No: 6 
Sample No. % Interference 
1 Nil 
 
 
RUGGEDNESS/INTERMEDIATE PRECISION 
The ruggedness of an analytical method is the degree of reproducibility of test results 
obtained by the analysis of the same samples under a variety of conditions, such as 
different laboratories, analysts, instruments, lots of reagents, elapsed assay times, assay 
temperatures or days. Ruggedness is a measure of reproducibility of test results under the 
variation in conditions normally expected from analyst to analyst, system to system. 
 
a) Different Days 
In this, criteria analyst carried the analysis on different days. The result is 
calculated as % of labeled amount of drug substance, RSD of assay results. It is said to 
be rugged if the assay result is within 98%-102% and the % RSD should be NMT 2%. 
The data results are being shown in Table-7 
TABLE-7 
Sample no 
Assay of Teneligliptin as % of labeled amount 
Day-01 Day-02 
1 99.68 99.69 
2 99.22 99.69 
3 99.43 99.13 
4 99.13 99.83 
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5 99.89 99.06 
6 99.98 99.62 
Average 99.55 99.50 
%RSD 0.35 0.33 
 
Acceptance criteria 
 
The all individual assays of Teneligliptin should be within 98% to 102%. Relative 
standard deviation of % assay results should not be more than 2.0% on two days. 
 
ROBUSTNESS: 
Robustness examines the effect of variation in operational parameters on the 
analysis results. For the determination of a method’s robustness, chromatographic 
parameters like mobile phase pH, mobile phase composition, flow rate, column 
temperature and variation in columns are varied within a realistic range and the 
quantitative influence of the variables is determined. If the influence of the parameter is 
within a previously specified tolerance, the parameter is said to be within the method’s 
robustness range. 
Measure of its capacity to remain unaffected by small, but deliberate variations in 
method parameters and provides indication of its reliability during its normal usage. 
Varying method parameters within a realistic range and the quantitative influence 
of the variables was determined, and, if the influence of the parameter was within a 
previously specified tolerance, then, the parameter was said to be within the method’s 
robustness range. 
Typical variations includes 
 Flow rate  
 Altered mobile phase Ratio  
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Table No: 8 
Altered Flow rate 
Sample no 
Assay of Teneligliptin as % of labeled amount 
Low Flow rate 0.4 ml High Flow rate 0.6 ml  
RT % RT % 
1  1.32 99.69 0.86 99.80 
2 1.32 99.75 0.86 100.09 
3 1.32 99.36 0.86 99.21 
4 1.32 99.64 0.86 99.72 
5 1.32 100.05 0.86 99.67 
6 1.32 99.16 0.86 99.44 
Average  99.61  99.65 
%RSD  0.31  0.31 
 
Table No: 9 
Altered Organic Phase ratio 
Sample no 
Assay of Teneligliptin as % of labeled amount 
Low Organic  Ratio 
(Buffer:ACN – 60:40) 
High Organic  Ratio 
(Buffer:ACN – 40:60) 
RT % RT % 
1  1.45 99.09 0.91 99.66 
2 1.45 99.23 0.91 99.87 
3 1.45 99.43 0.91 98.73 
4 1.45 99.49 0.91 100.08 
5 1.45 99.37 0.91 99.20 
6 1.45 99.19 0.91 99.11 
Average  99.30  99.44 
%RSD  0.16  0.51 
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SYSTEM SUITABILITY 
Flow rate: 0.5 mL/min     Injection volume: 2µL 
Wave length: 245nm     Temperature: Ambient 
SYSTEM SUITABILITY: BLANK 
 
Graph No- 01 
Injection 
Retention 
time 
Area 
Theoretical 
plates 
Tailing 
factor 
BLANK 0.0 0 0 0.00 
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SYSTEM SUITABILITY 
Flow rate: 0.5 mL/min     Injection volume: 2µL 
Wave length: 245nm     Temperature: Ambient 
SYSTEM SUITABILITY: STANDARD-1 
 
Graph No- 02 
Injection 
Retention 
time 
Area 
Theoretical 
plates 
Tailing 
factor 
STANDARD-1 1.02 1361.354 2125 1.05 
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SYSTEM SUITABILITY 
Flow rate: 0.5 mL/min     Injection volume: 2µL 
Wave length: 245nm     Temperature: Ambient 
SYSTEM SUITABILITY: STANDARD-2 
 
Graph No- 03 
Injection 
Retention 
time 
Area 
Theoretical 
plates 
Tailing 
factor 
STANDARD-2 1.02 1365.524 2123 1.05 
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SYSTEM SUITABILITY 
Flow rate: 0.5 mL/min     Injection volume: 2µL 
Wave length: 245nm     Temperature: Ambient 
SYSTEM SUITABILITY: STANDARD-3 
 
Graph No- 04 
Injection 
Retention 
time 
Area 
Theoretical 
plates 
Tailing 
factor 
STANDARD-3 1.02 1364.443 2124 1.05 
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SYSTEM SUITABILITY 
Flow rate: 0.5 mL/min     Injection volume: 2µL 
Wave length: 245nm     Temperature: Ambient 
SYSTEM SUITABILITY: STANDARD-4 
 
Graph No- 05 
Injection 
Retention 
time 
Area 
Theoretical 
plates 
Tailing 
factor 
STANDARD-4 1.02 1363.557 2126 1.06 
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SYSTEM SUITABILITY 
Flow rate: 0.5 mL/min     Injection volume: 2µL 
Wave length: 245nm     Temperature: Ambient 
SYSTEM SUITABILITY: STANDARD-5 
 
Graph No- 06 
Injection 
Retention 
time 
Area 
Theoretical 
plates 
Tailing factor 
STANDARD-5 1.02 1364.756 2125 1.06 
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SYSTEM PRECISION 
 
 
Graph No- 07 
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METHOD PRECISION 
STANDARD CHROMATOGRAMS 
 
 
 
Graph No- 08 
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LOW LEVEL (80 %) 
 
 
Graph No- 09 
MIDDLE LEVEL (100 %) 
 
 
Graph No- 10 
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HIGH LEVEL (120 %) 
 
 
Graph No- 11 
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ACCURACY (% Recovery) 
STANDARD CHROMATOGRAMS 
 
 
 
Graph No- 12 
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Spike Level 10 % 
 
 
Graph No- 13 
Spike Level 20 % 
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Graph No- 14 
Spike Level 30 % 
 
 
Graph No- 15 
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LINEARITY CHROMATOGRAMS 
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LINEARITY CHROMATOGRAMS 
 
Graph No- 16 
 
 
 
SPECIFICITY  
 
Graph No- 17 
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RUGGEDNESS 
 DAY-01 STANDARD CHROMATOGRAMS 
 
 
 
Graph No- 18 
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DAY-01 SAMPLE CHROMATOGRAMS 
 
 
 
Graph No- 19 
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DAY-02 STANDARD CHROMATOGRAMS 
 
 
 
Graph No- 20 
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DAY-02 SAMPLE CHROMATOGRAMS 
 
 
 
Graph No- 21 
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ROBUSTNESS 
LOW FLOW RATE (0.4 ml) STANDARD CHROMATOGRAMS 
 
 
 
 
Graph No- 22 
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LOW FLOW RATE (0.4 ml) SAMPLE CHROMATOGRAMS 
 
 
 
 Graph No- 23 
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HIGHFLOWRATE (0.6 ml) STANDARD CHROMATOGRAMS 
 
 
 
 
 
Graph No- 24 
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HIGH FLOW RATE (0.6 ml) SAMPLE CHROMATOGRAMS 
 
 
 
 
Graph No- 25 
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LESS ORGANIC RATIO STANDARD CHROMATOGRAMS 
 
 
 
 
 
Graph No- 26 
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LESS ORGANIC RATIO SAMPLE CHROMATOGRAMS 
 
 
 
Graph No- 27 
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MORE ORGANIC RATIO STANDARD CHROMATOGRAMS 
 
 
 
Graph No- 28 
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MORE ORGANIC RATIO SAMPLE CHROMATOGRAMS 
 
 
 
Graph No- 29 
Chapter-5                                                                                                       Results & Discussion  
 
RVS COLLEGE OF PHARMACEUTICAL SCIENCES , SULUR - 641402 Page88 
 
RESULTS AND DISCUSSION 
The new analytical method for the UHPLC method was established for 
Teneligliptin then optimized and then applied on pharmaceutical dosage forms. 
Various mobile phase systems were prepared and used to provide an appropriate 
chromatographic separation, but the proposed mobile phase comprising of Buffer and 
Acetonitrile in the ratio 50: 50 gave a better resolution and sensitivity. 
The detection was carried out by using UV detector at 245nm using Phenomenex  
Luna C18; 50 mm x 3.0 mm,3µm .Among the several flow rates tested, the flow rate of 0.5 
ml was found to be the best for Teneligliptin with respect to retention times and 
theoretical plates. 
The retention time is 1.02 for Teneligliptin. The asymmetry factor or the tailing 
factor was found to be 1.0 for Teneligliptin, which indicates symmetrical nature of the peak 
System suitability parameters such as retention time, tailing factor, capacity factor 
and number of theoretical plates were calculated. The number of theoretical plates was found 
to be around 2100 for Teneligliptin, which indicates efficient performance of the 
column.These parameters represent the specificity of the method. 
Linearity range was evaluated by the visual inspection of plot of peak area as a 
function of analyte concentration and the corresponding calibration graphs were shown in 
figure and results are shown in table.  
From the linearity studies, the specified concentration range was determined. It was observed 
that Teneligliptin was linear in the range of 50% to 150% for the target concentrations.  
The validation of the proposed method was verified by system precision and 
method precision. The %RSD for system precision and method precision of Teneligliptinwas 
tabulated. 
The validation of proposed method was verified by recovery studies. The 
percentage recovery range was found to be within the limits for Teneligliptin. This is a good 
Chapter-5                                                                                                       Results & Discussion  
 
RVS COLLEGE OF PHARMACEUTICAL SCIENCES , SULUR - 641402 Page89 
 
index of accuracy, specificity and repeatability of the method. The obtained results were 
tabulated.  
Placebo interference studies were made by injecting placebo alone, then the 
standard and the placebo along with the standard. They did not show any interference of 
placebo at the RT of the analyte peak 
Robustness studies were made by varying the flow rate and also by performing 
filter validation studies on to types of filters. The analytical data and results for filter 
validation were tabulated, hence the developed method was found to be robust.  
Study of ruggedness was made by conducting the study on different system and by 
two analysts. The results were found to be in limits and were tabulated and hence the 
developed method is found to be rugged. 
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Summary & Conclusion 
A simple, reproducible and efficient reverse phase Ultra high performance liquid 
chromatography (RP-UHPLC) method has been developed for estimation of Teneligliptin 
in its tablet dosage form. Separation was done by using mobile phase consists of Mixture 
of 1-OctaneSulphonic acid sodium salt (pH adjusted to 3.5 ±0.05 with Orthophosphoric 
acid): Acetonitrile (50:50,v/v). Chromatography separations were carried out on 
Phenomenex Luna C18 column (50 X 3.0mn; 3μm) at a flow rate of 0.5ml/min and UV 
detection at 245nm and the retention time for Teneligliptin is 1.02 minutes. The linear 
dynamic response was found to be in the concentration of 50μg-150μg/ml. The slope, 
intercept and Correlation coefficient was found to be 0.9996 respectively. The percentage 
recovery of Teneligliptin was found to be 99.50 - 100.06%. Proposed methods were 
found to be simple, accurate, precise and rapid and could be used for routine analysis.  
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